



# HHS Public Access

Author manuscript

*J Mol Biol.* Author manuscript; available in PMC 2015 April 23.

Published in final edited form as:

*J Mol Biol.* 2013 May 13; 425(9): 1461–1475. doi:10.1016/j.jmb.2013.01.027.

## The energy and work of a ligand-gated ion channel

**Anthony Auerbach**

Department of Physiology and Biophysics, State University of New York at Buffalo, Buffalo, NY 14214

### Abstract

Ligand-gated ion channels are allosteric membrane proteins that isomerize between C(losed) and O(pen) conformations. A difference in affinity for ligands in the two shapes influences the C $\leftrightarrow$ O ‘gating’ equilibrium constant. The energies associated with adult-type mouse neuromuscular nicotinic acetylcholine receptor-channel (AChR) gating have been measured by using single-channel electrophysiology. Without ligands the free energy, enthalpy and entropy of gating are  $G_0=+8.4$ ,  $H_0=+10.9$  and  $S_0=+2.4$  kcal/mol (–100 mV, 23 °C). Many mutations throughout the protein change  $G_0$ , including natural ones that cause disease. Agonists and most mutations change approximately independently the ground state energy difference, so it is possible to forecast and engineer AChR responses simply by combining perturbations. The free energy of the low $\leftrightarrow$ high affinity change for the neurotransmitter at each of two functionally-equivalent binding sites is  $G_B^{ACh}=-5.1$  kcal/mol.  $G_B^{ACh}$  is set mainly by interactions of ACh with just three binding site aromatic groups. For a series of structurally-related agonists there is a correlation between the energies of low- and high-affinity binding, which implies that gating commences with the formation of the low affinity complex. Brief, intermediate states in binding and gating have been detected. Several proposals for the nature of the gating transition state energy landscape and the isomerization mechanism are discussed.

### Keywords

allostery; acetylcholine receptor; gating; thermodynamics; ligand binding

---

Allosteric proteins are molecular switches that regulate the flow of material and information through metabolic and signaling pathways. These macromolecular systems isomerize between alternative conformational ensembles that have different functional outputs. The probability adopting each conformation is influenced by chemical, electrical, mechanical or thermal energy deposited from the environment at discrete ‘sensor’ sites in the protein. Different amounts of energy are deposited in the different shapes, so a change in the environmental energy forces a new conformational equilibrium to be established. The

---

© 2012 Published by Elsevier Ltd.

auerbach@buffalo.edu, 716-829-2435.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

sensors and the site(s) that regulate functional output are separated and communicate only by a global rearrangement of the system.

Here I discuss the thermodynamics of the allosteric process in adult mouse neuromuscular acetylcholine receptors (AChRs), five-subunit ligand-gated ion channels that mediate ion flux across cell membranes (Fig. 1a) (for reviews see ). This AChR is a model for understanding the molecular operation of a large superfamily of related receptor-channels that are present in many cell types, from prokaryotes to those in the human brain. Members of this group are modulated by a variety of ligands and are targets for toxins and drugs, both therapeutic and of-abuse.

AChRs can adopt more than two global shapes, but I will focus on the rapid (<ms) ‘gating’ conformational change in which the alternative ensembles have a closed (C) or an open (O) ion-conducting pathway. The neuromuscular AChR has two transmitter binding sites that receive energy from the extracellular solution in the form of a ligand concentration. Certain ligands (‘agonists’) bind with a higher affinity to O compared to C and, hence, reduce (make more negative) the relative free energy of the ion-conducting conformation. As a consequence, when agonists are present at the binding sites the probability of being open increases.

Below, I first discuss the thermodynamic cycle for ligand binding and channel gating. I then consider the relative ground state energies that determine the gating equilibrium constant, either without or with ligands at the binding sites. Third, I outline several hypotheses that have been proposed for the mechanics of the isomerization itself. This perspective is based on the groundbreaking theoretical framework developed first for hemoglobin <sup>4</sup> and later applied to AChRs <sup>5</sup>, and follows the pioneering single-channel experiments of Jackson .

## II. The Cycle

The above definition of allostery describes a thermodynamic cycle (Fig. 1b). The letters represent the reaction ground states (energy wells) and the arrows represent the transition states (energy barriers), for which crossing involves movements or changes in the dynamics of structural elements. The core assumption of the model is that same, essential C↔O conformational change occurs either without or with agonists (A) at the transmitter binding sites.

The free energy differences between the ground states of the isomerization are  $G_0$  ( $G_O - G_C$ ; unliganded gating) and  $G_2$  ( $G_{A2O} - G_{A2C}$ ; diliganded gating). The horizontal arrows represent the exchange of ligand binding energy at two sensor sites that for ACh and the adult mouse AChR happen to be approximately functionally-equivalent. The free energy for binding to the lower-affinity, C shape is  $G_{LA}$  and that for the higher-affinity, O shape is  $G_{HA}$ . From detailed balance,  $2 G_{LA} + G_2 = G_0 + 2 G_{HA}$ . Rearranging, and defining  $G_B$  as the net binding free energy from each ligand ( $G_{HA} - G_{LA}$ ),

$$\Delta G_2 = \Delta G_0 + 2\Delta G_B \quad \text{Eqn. 1}$$

$G_B$  is the average amount of free energy generated by the affinity change for the agonist at each transmitter binding site that ultimately contributes to the increased relative stability of  $A_2O$  vs.  $A_2C$ .

Although the cycle provides a satisfactory, first-order description of AChR gating<sup>8</sup>, experiments have shown that the scheme is incomplete. There is evidence that the  $C \leftrightarrow O$  and  $A_2C \leftrightarrow A_2O$  transitions occur through one or more intermediate steps that are not fully-resolved in the single-channel current record. In channel-opening, intermediate structures are adopted, briefly, that are no longer  $C$  but not quite yet  $O$ . Given the AChR's size (~300 kD), there undoubtedly are many small wells populating the isomerization energy landscape. The patch clamp instrument has a limited bandwidth and sojourns in states having lifetimes  $< \sim 30 \mu s$  are typically not resolved as discrete events.

The  $G_2$  values that we measure are the energy differences between the end states of the isomerization and, hence, their magnitudes are not dependent of the number or character of the intermediates. For example, the simplest extended kinetic scheme for diliganded gating is  $A_2C \leftrightarrow A_2F \leftrightarrow A_2O$ , where  $F$  represents a single intermediate state. In this scheme the apparent  $G_2$  is simply the sum of the energy changes for each of the two steps.

There are also intermediate states within the binding arrows of the cycle. There is evidence that the LA association of some agonists is not by diffusion alone but also requires a conformational change of the protein that may involve an inward displacement ('capping') of loop C at the transmitter binding site (see Fig. 5)<sup>9</sup>. The cycle only specifies two affinity states, but the binding site apparently can adopt three different conformations (apo, LA and HA) that are connected by two structural rearrangements called 'catch' ( $apo \leftrightarrow LA$ ) and 'hold' ( $LA \leftrightarrow HA$ ). In the cycle, the LA 'catch' rearrangement lies within the binding arrows and the HA 'hold' rearrangement lies within the gating arrows.

An important observation is that for some structurally-related ligands  $G_{LA}$  and  $G_{HA}$  are correlated, to an extent that the diliganded gating equilibrium constant can be predicted only from knowledge of the agonist's low-affinity association rate constant. For this agonist series at least, the  $apo \leftrightarrow LA$  energy (structure) change and the  $LA \leftrightarrow HA$  change appear to be two stages of a single, integrated process called 'catch-and-hold'. This correlation in energies joins the horizontal and vertical arrows of the cycle and blurs the distinction between binding and gating that is implicit in the model.

If 'catch-and-hold' is an integrated structural rearrangement of the binding site, then gating can be considered to start with the formation of the LA complex, which occurs within the binding arrows of the model. The 'catch' conformation change appears to be sufficient (but not necessary) to modify the channel-opening rate constant, either by lowering the gating transition state barrier, modifying the rate constant prefactor or both. The evidence suggests that the subsequent  $LA \rightarrow HA$  transition serves only to stabilize the  $O$  conformation rather to initiate the isomerization. As discussed below, the 'hold' rearrangement may occur at any point within the global  $A_2C \leftrightarrow A_2O$  reaction.

## II. Ground State Energies

### Measurements

It is possible to measure experimentally  $G_2$  and  $G_0$  by using single-channel electrophysiology, and with high precision ( $\sim\pm 0.2$  kcal/mol) (Fig. 2). When the concentration of the agonist ( $[A]$ ) is sufficiently high, channel openings occur in clusters that reflect the activity of a single AChR. In addition to  $C\leftrightarrow O$  gating, AChRs can take on ‘desensitized’ conformations that are non-conducting (like C) but have a high affinity for agonist (like O). In neuromuscular AChRs the rate constants for desensitization and recovery are much slower than those for binding and gating and, hence, serve to isolate periods of activity arising from individual AChRs. This isolation, and the fact that AChRs are ion channels, offer a huge advantage for studying the allosteric process because it provides a long-lasting signal from single molecules at a  $\sim 30$   $\mu$ s time resolution.

When  $[A]$  is much greater than the LA equilibrium dissociation constant ( $K_d$ ), most of the fully-resolved current intervals within clusters reflect  $A_2C\leftrightarrow A_2O$  gating. The rate constants are estimated from the intra-cluster shut and open interval durations, and their ratio gives the diliganded gating equilibrium constant,  $E_2$ .  $G_2$  is proportional to the natural logarithm of this equilibrium constant ( $G_2$  in kcal/mol =  $-0.59\ln E_2$ ). For mouse adult-type neuromuscular AChRs at a membrane potential of  $-100$  mV and at  $23$  °C,  $E_2^{ACh}=25$  and  $G_2^{ACh}=-1.9$  kcal/mol.

It is a bit more difficult to estimate  $G_0$  because the unliganded  $C\leftrightarrow O$  gating equilibrium constant of wt AChRs is small and openings are not clustered. However, many background mutations increase this equilibrium constant sufficiently to generate clusters (Fig. 3a)<sup>12</sup>. Desensitization proceeds mainly from the O state and with a rate constant that is approximately the same regardless of whether or not ligands occupy the binding sites. By assuming that each mutation only changes  $G_0$  (and not  $G_B$ ) and does so independently of others, it is possible to extrapolate the apparent unliganded gating equilibrium constant to the wild-type condition (Fig. 3b). The slope of the line for one set of mutant combinations (filled circles) is exactly that predicted if the change in  $G_2$  was equivalent that in  $G_0$ , indicating that both assumptions were valid. For another mutant set (open circles) the slope was slightly smaller than predicted, probably because of some energy coupling between the mutations. From these experiments, based only on brief unliganded openings,  $G_0=+8.3$  kcal/mol ( $-100$  mV,  $23$  °C)<sup>13</sup>.

There is another way to estimate  $G_0$ . With ACh, each of the two adult-type AChR transmitter binding sites provides the same amount of ‘hold’ energy, hence,  $G_2 - G_1 = G_1 - G_0$ . Because we know  $G_2$ , all that is necessary in order to calculate  $G_0$  is to measure  $G_1$ . The binding site mutation  $\alpha$ W149M greatly reduces  $G_B^{ACh}$  but has almost no effect on  $G_0$ <sup>14</sup>. By examining clusters of currents ( $-100$  mV) from AChRs having this mutation at just one binding site it was estimated that  $G_1^{ACh}=+3.3$  kcal/mol, or that  $G_0=+8.4$  kcal/mol<sup>15</sup>. The same result for  $G_0$  was obtained using the partial agonist choline. That the extrapolation method and the monoliganded method give the same quantitative result for  $G_0$  demonstrates that brief unliganded openings and longer mono- and diliganded openings

are generated by the same essential, global isomerization. This observation confirms the core assumption of the cyclic scheme.

A negative membrane voltage stabilizes the O conformation. By measuring  $G_0$  at different membrane potentials it was found that the intrinsic chemical energy of gating (at 0 mV) is +9.4 kcal/mol. This energy reflects gating of AChRs with only water at the transmitter binding sites, because the removal of monovalent cations from the extracellular solution has no effect on  $G_0$ <sup>13</sup>.

From Eqn. 1, 2  $G_B^{ACh} = -10.2$  kcal/mol (this value is not voltage-dependent). Because equal energies are provided by each ACh molecule,  $G_B^{ACh} = -5.1$  kcal/mol.

### The intrinsic gating free energy, $G_0$

The effect of mutations on gating has been measured from single-channel currents for >1000 mutations of >100 residues in many different regions of the AChR (see<sup>8</sup>). Two essential features of the mutational energy changes emerge from these studies<sup>11</sup>.

First, mutations away from the binding sites change  $G_2$  and, hence, dose-response curves by an approximately-equivalent change in  $G_0$ . To a good approximation,  $G_B$  and  $K_d$  are not altered by non-binding-site mutations. The energy from the agonist affinity change appears to be determined by a small, select group of amino acids immediately at the binding sites. In AChRs, most changes in cellular responses consequent to side-chain substitutions can be attributed to a change in the relative stability of unliganded C vs. unliganded O.

Second, the  $G_0$  energy changes are mostly independent. In mutant cycle analysis the combined effect of two mutations is compared to the sum of the energy changes for each mutation separately. More than 50 such pair-wise combinations have been tested, and in most cases the net and sum energies are similar. Also, the effects of most background mutations are independent of the agonist and, hence, of  $G_B$ . There are, however, some exceptions. There is a small-but-measurable amount (~0.5 kcal/mol) of long-distance energy coupling between side chains apparent across the protein that is a bit larger than the resolution limit of the analysis. This low-level, background coupling may be a clue for understanding how the binding sites and the gate are linked energetically (see below). Also, some closely-apposed side chains at the extracellular-membrane domain (EM) interface interact more strongly, by ~1–2 kcal/mol. In some cases, however, the reported degree of interaction here may have been overestimated because  $G_2^{ACh}$  values for the single mutants  $\alpha P272A$  and  $\alpha E45A$  were underestimated. Also, one residue pair in the extracellular domain ( $\alpha A96$  and  $\alpha Y127$ ) has been found to interact by ~6 kcal/mol, suggesting that these two side chains act effectively a single structural unit in the gating isomerization<sup>20</sup>.

These two essential qualities of mutational effects suggest that i) most mutations change  $G_0$  simply because the substituted side chain is relatively more (or less) stable in O vs. C compared to the wt side chain, and ii) the structural changes (in bonds, water and dynamics) associated with mutational gating free energy changes occur close to the site of the mutation. The simplest explanation for independence is that the energy changes are local because multiple, long range energy transfers would be expected to interact. The energy of the gating

transition state is linked to those of the C and O ground states, so a perturbation(s) that changes  $G_0$  will also change the forward and backward rate constants of the isomerization and the kinetics of the cellular response. To a first approximation, in AChRs mutations and agonists alter functional responses by changing the relative energies of the gating ground states, mainly by local interactions.

There are likely to be rigid body motions of domains and secondary structures within the AChR isomerization, for example a rotation of the extracellular  $\beta$ -sandwich and tilting movements of the pore-lining M2 transmembrane helices. However, the essential independence of the effects of mutations on these domains suggests that the side chain substitutions do not affect generally these motions, insofar as each amino acid changes energy independently of others on the rigid structure. Because of the independent nature of side chain energy changes, it appears to be possible to make of map of gating energy changes, residue-by residue, that can be superimposed approximately on the map of electron densities.

That most side chain substitutions change only  $G_0$  and do so nearly independently has implications with regard to engineering AChR function. First, natural selection of AChRs appears to be mainly about setting the intrinsic C vs. O ground state energy difference. Most mutations decrease  $G_0$ , so survival apparently is enhanced when constitutive activity is low. Some myasthenic syndromes<sup>24</sup> and epilepsies<sup>25</sup> are caused by AChR mutations that make  $G_0$  less positive<sup>26</sup>. As a consequence, ions leak into cells, synaptic currents are prolonged and choline, a natural breakdown product of ACh, becomes a stronger, perhaps-inappropriate signal<sup>27</sup>. The fact that the effects of side chain substitutions on  $G_0$  are nearly independent makes the process of natural selection stable. If a mutation to one residue had an effect on  $G_0$  that depended on the side chain at another position, then assessing its selective advantage would be more problematic. It appears that survival is optimized, stepwise, by random mutations that alter  $G_0$  nearly independently.

Second, it is easy to design and control AChR properties in the laboratory<sup>11</sup>. The effect of a combination of mutations of  $G_0$  and the liganded gating rate equilibrium constants can be forecast simply by adding each separate energetic effect. Because mutations away from the binding site typically do not change  $G_B$  (or  $K_d$ ) regardless of the agonist, the ligand energy, too, can be added to this sum to predict  $G_2$  and the cellular response (Eq. 1). This engineering capability means that it is possible to quantify rate constants that are either too fast or too slow to be measured accurately in wt AChRs simply by adjusting the  $G_0$  of the background construct.

### The map of $G_0$

Of the many mutational changes in  $G_0$  that have been measured so far, only ~15% have little or no effect (<0.5 kcal/mol) and most of the rest make  $G_0$  less positive (Fig. 4a, top). Mutations in many different regions of the protein change  $G_0$  but the spatial distribution is not random (Fig. 4b, left). Larger effects are apparent for amino acids located between the binding site and the gate. The range in  $G_0$  for a series of mutations of one residue is one way to quantify the sensitivity of a position in the gating isomerization. In this active zone

mutations of amino acids in all secondary structures of the  $\alpha$  subunits can generate substantial range-energies ( $>2$  kcal/mol).

In the extracellular domain, a column of residues located at the  $\alpha$ - $\epsilon$  and  $\alpha$ - $\delta$  subunit interfaces show the largest range-energies changes in the C $\leftrightarrow$ O isomerization (4 kcal/mol)<sup>20</sup>. This is consistent with the idea that this region of the protein experiences large, local energy changes between C and O. The largest range measured so far is for an alanine in loop A ( $\alpha$ A96; 8.1 kcal/mol), where a histidine substitution (in both  $\alpha$  subunits) increases the unliganded gating equilibrium constant by a factor of  $\sim 100,000$ <sup>28</sup>. A nearby tyrosine also has an extraordinarily large range-energy. It so happens that these are the exceptional, tightly-coupled amino acid pair<sup>28</sup>. The large range-energies of  $\alpha$ A96 and  $\alpha$ Y127 mutations indicate that these two positions experience a large C vs. O energy change in their local environment. These amino acids also have similar phi-values, which indicates that the energy changes of the elements of this structural unit occur synchronously (see below).  $\alpha$ A96 and  $\alpha$ Y127 are close to a hydrophilic pocket in the interior of the  $\alpha$ -subunit extracellular domain, but the large range-energies likely reflect only the ground state energy difference and do not shed light on the hypothesis that this region confers structural flexibility for the gating isomerization itself<sup>29</sup>.

Some residues buried within the core of the extracellular domain do not show a significant effect on  $G_0$ , so this compact region may remain iso-energetic between C and O<sup>31</sup>. There are large changes in  $G_0$  apparent with mutations of some residues at the EM interface, mainly in the  $\alpha$  subunit. In the membrane domain, near the C-terminus (extracellular limit) of the M2 helix, there is a cluster of amino acids that have large range-energies, but apparently only in the  $\alpha$  subunit<sup>38</sup>. At the M2 gate region, near middle of the pore (positions 9', 12' and 13'), residues in all subunits show substantial  $G_0$  changes, in all subunits. A large energy change implies a significant change in the local side chain environment between C and O, perhaps from water entry here. Range-energies of 1–3 kcal/mol have been observed for amino acids in the M3 and M4 helices of the  $\alpha$ -subunit. The effects of mutations of residues in the M1 helix<sup>46</sup> and the intracellular domain (not shown in Fig. 4) of the  $\alpha$  subunit, and the extracellular and other domains of the non- $\alpha$  subunits, have not been studied in detail with regard to  $G_0$ .

### Free energy from the ligand, $G_B$

$G_B$  is the energy of stabilization to the O ground state provided by the LA $\rightarrow$ HA 'hold' conformational change at the binding site. The LA 'catch' rearrangement effectively adds a new, side-chain-sized structural element (the agonist) to the binding site that is more stable in O compared to C. In this sense, agonist  $G_B$  values are similar to mutational  $G_0$  changes: they are consequences of structural rearrangements that change the relative stability of O vs. C mainly by local interactions. Eq. 1 could be rewritten as

$G_2 = G_0^{wt} + G^P$ , where  $G^P$  is sum of the free energy changes to the ground states caused by all perturbations, including voltage, side chain substitutions and newly-added ligands.

The binding energies for some 'physiological' ligands of AChRs have been measured. At the neuromuscular synapse the neurotransmitter ( $G_B^{ACh} = -5.1$  kcal/mol) is hydrolyzed to

choline ( $G_B^{\text{choline}} = -3.3$  kcal/mol), which can be oxidized to betaine ( $G_B^{\text{betaine}} = -1.9$  kcal/mol). Nicotine is the predominant tobacco alkaloid ( $G_B^{\text{nicotine}} = -4.1$  kcal/mol).  $G_B$  values for some agonists are given in Table 1.

Although most mutations change only  $G_0$ , a handful of residues at the transmitter binding sites are important in setting  $G_B$ . Each binding site is a discrete apparatus that has evolved to derive binding energy from ligands to enforce the gating conformational change. So far the operation of this ‘engine’ has been investigated by estimating  $G_B^{\text{ACh}}$  in AChRs having mutations of eight binding site residues (Fig. 5).

There are five conserved aromatic amino acids at each binding site. Just three of these, an  $\alpha$ -subunit ‘aromatic triad’ comprised of TrpB, TyrC1 and TyrC2, contribute significantly to  $G_B^{\text{ACh}}$ <sup>49</sup>. The indole or benzene groups of these side chains each contribute  $\sim 2$  kcal/mol to  $G_B^{\text{ACh}}$ <sup>49</sup> by cation- $\pi$  interactions. In adult-type AChRs, the two other aromatic groups (TrpD and TyrA) make little or no contribution to  $G_B^{\text{ACh}}$ .

The removal of the hydroxyl groups from TyrC2 and TyrA have almost no effect on  $G_B^{\text{ACh}}$ , but a Y-to-F substitution at TyrC1 makes this energy more positive by  $\sim 2$  kcal/mol. It is likely that this reduction in binding energy is not directly from losing an interaction with the quaternary ammonium group of ACh, but rather from one with a nearby lysine<sup>52</sup>.

Two glycines in loop B bracket TrpB. All mutations of GlyB1 reduce activation (by making  $G_0$  and  $G_B$  more positive and by increasing  $K_d$ ) whereas all those of GlyB2 increase activation (by making  $G_0$  less positive and by reducing  $K_d$ , with little effect on  $G_B$ ). Given its location in AChBP structures, the  $G_B$  energy arising from GlyB1 is probably not from a direct interaction with the ligand. The fact that GlyB2 mutations alter  $K_d$  but not  $G_B$  indicates that these substitutions increase the low and high affinities of the binding site to nearly equivalent extents. Some substitutions of ProD2 (on the complimentary face of the pocket) make  $G_B^{\text{ACh}}$  more positive by  $>2$  kcal/mol, with the larger effects apparent at the  $\alpha$ - $\epsilon$  vs.  $\alpha$ - $\delta$  binding site (unpublished observations).

This list of structural elements that contribute to  $G_B^{\text{ACh}}$  is probably not complete and may be different at the two binding sites, for different agonists and for different AChR subtypes. Energetic interactions between groups that influence  $G_B$  have not been examined in detail, nor have the sources and magnitudes of binding energy for agonists other than ACh. Our understanding of the AChR binding sites is in its infancy.

## Temperature

It is possible to dissect free energy into enthalpy and entropy components by measuring AChR binding and gating equilibrium constants at different temperatures<sup>56</sup>. The temperature dependence of the diliganded gating equilibrium constant depends on the agonist (Fig. 6a). For ACh, carbamylcholine and choline, the gating enthalpy differences are approximately the same as the  $G_B$  free energy differences. This suggests that  $G_B$  is essentially all enthalpy and that little heat is generated by the low-to-high affinity change.



With this information, the intrinsic enthalpy change of the unliganded gating isomerization ( $H_0$ ) has been estimated. From Eq. 1, the enthalpy change for diliganded gating ( $H_2$ ) is the sum of those for the affinity change ( $2 H_B$ ) and  $H_0$ . The measured value is  $H_2^{ACh} = +0.7$  kcal/mol (at  $-100$  mV). Because  $2 H_B \approx 2 G_B = -10.2$  kcal/mol, we calculate  $H_0 \approx +10.9$  kcal/mol, which is equivalent to breaking just a few hydrogen bonds. From the relationship  $G_0 = H_0 - T S_0$  (where  $T$  is the absolute temperature and  $S$  is the entropy) and the value  $G_0 = +8.4$  kcal/mol, we estimate that  $S_0 = +8.5$  cal/mol-K ( $+2.4$  kcal/mol at  $23$  °C). At room temperature,  $\sim 20\%$  of the total energy of unliganded gating is heat ( $=T S_0$ ).

There are other good reasons to separate free energy into enthalpy and entropy components. When we compare structural models of a protein in C vs O we focus our attention on the changes in atomic positions and bonds. These differences relate more closely to enthalpy than to free energy because the entropy changes (from dynamics or solvent) are mostly invisible in the structures. Also, enthalpy changes are typically larger than free energy changes because of compensating changes in entropy (Fig. 6b). For example, for the mutation  $\alpha W149N$ ,  $H_0$  is  $+7.4$  kcal/mol while  $G_0$  is only  $-0.5$  kcal/mol<sup>57</sup>. A map of  $H_0$  will provide a larger signal regarding changes in bonding than that of  $G_0$ . An enthalpy mutant-cycle analysis shows that the enthalpy changes caused by mutations of different residues can be approximately independent (Fig. 6c), so this map could show the spatial distribution of heat exchange in the conformational transition.

With ACh as the agonist, the gating equilibrium constant has very little temperature dependence. However, temperature has a large ‘catalytic’ effect and substantially influences both the forward and backward isomerization rate constants. This indicates that there is a large ( $\sim 20$  kcal/mol) enthalpy component to the gating transition state barrier. The free energy of this barrier for diliganded gating has been estimated to be  $\sim 5$  kcal/mol so large, compensating entropy changes likely prevail within the isomerization. The AChR appears to be partially ‘unfolded’ in the gating transition state ensemble.

The independence of mutational effects on  $G_0$  also applies to the transition state. By combining mutations that, for example, increase both the forward and backward gating rate constants it is possible to engineer the kinetics of the AChR response, including at different temperatures.

### III. Gating Transition State

#### Intermediate gating states

A thermodynamic cycle is useful for estimating the relative ground state potential energies but provides little information about the energy transfer between the binding sites and the gate. This energy transfer defines the mechanical work and transition state ensemble (TS) of the isomerization itself. Presumably, the system is at all times in thermal equilibrium and there are no large-scale, ballistic gating motions. The assumption is that within the isomerization the moving parts are displaced in straight lines and with constant velocities only for short times ( $< ns$ ) before collisions slow them and randomize their directions.

Mutations, ligands and voltage change the relative ground state free energies to force the global isomerization and establish a new equilibrium, but the process by which one protein shape converts to another is not revealed by measurements of these potential energies. It is therefore important to separate ‘coupling’ as defined by the thermodynamic linkage between ligand/voltage and ground state potential energies given by the cycle, and ‘coupling’ as defined by the actual mechanical work of the isomerization. To understand the details of the reversible energy flow between the binding sites and the gate (and elsewhere) we must go within the arrows of the cycle and examine the nature of gating TS.

One way to approach this problem is by investigating the short-lived states that exist between the C and O ground states. There are several lines of evidence indicate that such intermediate states can be detected in single-channel currents. The standard sequential model for activation by agonists is  $A \leftrightarrow AC \leftrightarrow A_2C \leftrightarrow A_2O$ . This scheme is just a section of the full cycle that ignores sojourns in O and AO that are rare under physiological conditions. Kinetic modeling studies indicate that an extra, brief AC’ state interposed between AC and  $A_2C$  improves the statistical fit of the interval durations. One interpretation is that ligand energy from each binding site is transferred independently towards the gate, with rapid opening happening only after both transfers have taken place<sup>62</sup>. Accordingly, AC’ could be a gating intermediate in which only one of the two transfers has occurred.

Other direct evidence for gating intermediates has come from analyses of open-channel currents. The open current has excess, high-frequency noise (compared to the baseline) that does not arise from instrumentation or shot sources but from rapid interruptions in the channel current<sup>63</sup>. Advanced analysis methods have been used to extract directly a  $\sim 5 \mu\text{s}$  closing event (‘flip’) from this signal<sup>64</sup>. Neither the amplitude nor lifetime distribution of this gap is fully-resolved, nor can its placement within a state model for activation be established unambiguously. However, if it is assumed that ‘flip’ is a full closure that occurs between  $A_2C$  and  $A_2O$ , then it is a non-conducting intermediate state. If it is further assumed that its lifetime is distributed as a single exponential, then it reflects just one such state. The detection of ‘flip’ is significant because it offers the possibility that states between C and O can be probed directly by using discrete Markov models, and that  $G_0$  can be separated into its addends.

Another way to investigate intermediate gating states is by rate-equilibrium analysis. Although each gating rate constant is estimated independently (as a free parameter), in many chemical reactions, including AChR gating, the forward and backward rate constants for series of mutations of one amino acid are correlated inversely<sup>65</sup>. For example, AChR mutations that decrease  $G_0$  do so by increasing the forward and decreasing the backward gating rate constants, to varying extents. This correlation can be quantified by plotting (on a log-log scale) the forward rate constants vs. the equilibrium constants for a series of mutations of one amino acid.

The slope of this relationship is called phi. In AChRs the values of the rate constants can vary by orders of magnitude, but the correlation remains constant. The interpretation of phi is complex and not founded in a definitive theory. It could reflect the height of the transition state barrier relative to that of the product state, the rate constant prefactor (specifically, the

transmission coefficient)<sup>68</sup> or, perhaps, both. However, there is some agreement that it provides information about the relative timing of the energy (structure) changes of the perturbed site within the channel-opening reaction, on a scale from 1 (earlier) to 0 (later).

Gating phi values have been measured for mutations of many AChR residues, and, remarkably, there is a spatial organization (Fig. 4b, right). Phi values of residues near the transmitter binding sites are high (earlier), those near the gate are low (later), and those in between are intermediate. As shown in Fig. 4b, in opening the sequence of energy changes is purple-blue-green-red, and in closing this order is reversed.

Another feature of the map is that residues having similar phi values are clustered into contiguous groups. There appears to be 4 such clusters, which suggests that there are at least three intermediate states interposed between A<sub>2</sub>C and A<sub>2</sub>O<sup>28</sup>. The approximately longitudinal, decreasing gradient of phi values suggests that in opening the clusters move in sequence, starting with the binding site and ending with the gate (but see below). This led to the proposal that the AChR isomerization is a diffusional process. The suggestion is that if we could look inside the protein with ~ns time resolution, the domain movements would appear as a Brownian conformational ‘wave’ between the sensors and the gate<sup>69</sup>.

There are two curious characteristics of the phi map. First, there is an isolated patch of residues at the C-terminus of the M2 helix in the  $\alpha$  subunit (the  $\alpha$ M2 cap) that has among the largest range energies (blue) and highest phi-values (purple) in the protein (Fig. 4b)<sup>38</sup>. The phi values for some amino acids in this region appear to be even higher than those for residues at the transmitter binding sites. This raises the possibility that the first domain to move in channel opening is not the binding site, but, rather, the  $\alpha$ M2-cap. It may be relevant that a recent crystal structure of the AChR homolog GLIC shows a protein mostly in the O conformation but with this portion of the M2 helix locally in the C position<sup>70</sup>. Although this observation is consistent with the idea that phi-clusters move as discrete structural units, it is unclear if the locally-closed GLIC structure represents a gating intermediate state or, perhaps, a desensitized conformation.

The second notable feature of the map is that phi values of binding site elements appear to be mutable. The phi values of all binding site residues measured so far are higher in diliganded vs. unliganded gating. For the eight residues shown in Fig. 5, the average diliganded phi is 0.93 (range, 0.88–1.0) and the average unliganded phi is 0.76 (range, 0.68–0.89). Residues away from the binding sites apparently do not show such mutability<sup>12</sup>, which suggests that the phi-shift may be caused by events local to the binding sites rather than by a shift in the position of the overall TS barrier. It is possible that the position of the LA $\leftrightarrow$ HA ‘hold’ conformational change within the global isomerization can be influenced by experimental conditions.

Phi analysis is silent with regard to the conductance status of the intermediates. However, ‘flip’ as an intermediate gating state has a high affinity for the agonist and a non-conducting pore. This description applies to desensitized states as well. It is possible that the slow rate constant for desensitization could reflect a much faster process proceeding from a brief, non-conducting gating intermediate state<sup>69</sup>.

Flip and phi are in good agreement, with the main incongruence being with regard to the number of brief intermediate states (one vs. several). One possibility is that flip underestimates the number of TS energy wells. The distribution of flip lifetimes is not fully-resolved, so it may be that these events reflect the tail of a multi-exponential distribution that appears in experiments as a partially-resolved, single exponential because of the limited time resolution of the patch clamp. Another possibility is that phi overestimates the number of intermediates. Phi quantifies side chain energy changes, and there is no reason to assume that an amino acid is perturbed only once during the isomerization. For example, assuming that there is only one intermediate state ( $C \leftrightarrow F \leftrightarrow O$ ), phi could reflect a weighted average of the energy changes occurring in the  $C \leftrightarrow F$  entry step vs. the  $F \leftrightarrow O$  exit step<sup>40</sup>. In this case the purple residues in Fig. 4b would change energy mainly in the entry step, the blue and green residues in both exit and entry (to different extents) and the red residues mainly in the exit step. The number and conductance(s) of the gating intermediates is an open question.

### Site-gate energy transfer

Electrophysiology experiments indicate that there are one or a few metastable intermediate states between C and O. What are their structural correlates, and what are the forces that motivate energy flow between the binding sites and the gate? Mutational changes in  $G_B$  and  $G_0$  and phi values provide information regarding which structural elements change energy (move) in gating and in what order, but they do not illuminate the forces that underlie these energy changes. There have been several proposals for the isomerization mechanism, but as yet no consensus has emerged.

With ACh molecules bound to wt AChRs in low-affinity complexes at both binding sites, the opening isomerization rate constant is ~10 million times faster than when only water is present. The event that triggers this dramatic change in the gating TS appears to be the 'catch' rearrangement, which probably involves partial loop C capping. In this regard, the AChR gating isomerization commences with the low-affinity binding of agonists.

What happens next? It is important to emphasize that there is no *a priori* reason to assume that the subsequent gating rearrangements begin at any particular place in the protein. Because everything is in thermal equilibrium, neither the agonists at the binding site nor the ions in the pore have any significant momentum. The energy from the LA→HA affinity change may occur at any point in the isomerization: the onset, middle or end, and either before or after the low→high conductance rearrangement of the pore. (If 'flip' is a gating intermediate, then it suggests that 'hold' precedes the conductance change). The LA→HA switch serves only to stabilize the O ground state, mainly by local interactions with the aromatic triad. The mechanical work of gating could begin anywhere and proceed in any sequence.

The 'priming' hypothesis for work is related to the AC' intermediate state inferred from kinetic modeling. In this scheme, agonist HA binding causes an inward displacement of loop C at each transmitter binding site that transfers energy independently to the EM interface via a motions of secondary structures, most likely  $\beta$ -strands 9–10<sup>17</sup>. This perturbs a proline<sup>73</sup> and, perhaps, a salt bridge<sup>17</sup> at this interface and, eventually, the pore-lining M2 helix, to initiate ion conduction.

There is evidence, however, that many of the experimental results presented in support of this hypothesis reflect perturbations of the ground state energies rather than of the energy transfer process. For instance, brief unliganded openings, purportedly generated by ‘singly-primed’ AChRs (in which energy from only one binding site has been transferred to the gate region), are in fact from AChRs that have had the same amount of energy transferred to the gate as with two ligands present. We know this because  $G_0^{\text{wt}}$  estimated only from these brief unliganded gating events, and  $G_0^{\text{wt}}$  estimated from di- and monliganded gating events, are the same. Also, the deletion of loop C, the proposed structure that triggers the ‘priming’ energy transfer, debilitates agonist binding but has almost no effect on unliganded gating (unpublished observations). LA capping appears to be sufficient to increase the opening rate constant, but not necessary. The effect of loop C cross-linking and the evidence for a specific energy transfer pathway can be explained by alterations in the C vs. O ground state energies rather than to alterations in the transfer process. Mutations of the key proline and salt bridge residues at the EM interface do not cripple gating. Further, phi values suggest that in channel opening the  $\alpha$ M2 cap moves (changes energy) before rather than after the interface. The hypothesis that the AChR gating isomerization occurs by a specific pathway involving top-down, sequential motions of secondary structures and select residues at the EM interface is appealing from the perspective of structure, but this idea is not supported by experiments.

In the ‘Brownian wave’ model for gating it is proposed that the isomerization of each phi-cluster triggers that of its neighbor<sup>69</sup>. In this mechanism the motions of the backbone and side chains in each group transfers energy to the adjacent one, and so on through the protein. In support of this hypothesis, the phi-clusters coincide roughly with structural domains that adopt alternative positions in C vs. O in the prokaryote homologues of the AChR, ELIC and GLIC. However, mutations of key residues at cluster boundaries do not change the map of phi, and, importantly, the longitudinal gradient in phi is neither absolute nor fixed. Specifically, the phi values of residues in the i)  $\alpha$ M2-cap appear to be the highest in the protein, ii) membrane domain are not organized longitudinally, ii) presumably-rigid  $\alpha$ M2 helix are inhomogeneous, and iv) binding sites are mutable<sup>76</sup>.

The ‘wave’ hypothesis for site-gate communication is appealing because it rationalizes much of the phi map. However, this map may be an effect, rather than a cause, of the mechanical work of gating. It is likely that the amino acids change energy in the sequence given by their phi values, but the forces that generate this sequence may be independent of side chain and domain energy changes that may serve only to set the relative stability of C vs. O.

Another hypothesis, called the ‘quaternary twist’, has been proposed based on elastic network model (ENM) analyses of the whole protein backbone<sup>77</sup>. Using a homology model of the  $\alpha$ 7 AChR, movement along the softest mode widens and narrows the pore, as expected for a gating transition. However, the pore-widening mode was not apparent in the simulations using prokaryote receptor structures. Interestingly, interpolated ENMs, using ELIC (presumably closed) and GLIC (presumably open), predict a spatial distribution of phi values that is, to some extent, consistent with the experimental map<sup>78</sup>. It is possible that

motions of the backbone generate the forces that result in a 'Brownian wave' of side chain energy changes, like branch movements shaking the leaves of a tree.

It may be relevant is that there is small-but-measurable amount of background  $G_0$  energy coupling ( $\sim 0.5$  kcal) between widely-separated side chains. For example, mutant-cycle analysis indicates that the ProD2 residues at the two binding sites are coupled by  $\sim 0.7$  kcal/mol, which is slightly larger than the experimental resolution (unpublished observations). These low-level coupling energies could reflect a long-range transfer of energy, for instance by the backbone breathing motions. In the 'quaternary twist' mechanism the binding site and the gate communicate *via* the collective motion of all of the backbone atoms. It may be that there not a discrete communication pathway between the binding sites and the gate.

## Final Thoughts

Cellular responses emerge from complex combinations of rate and equilibrium constants. The constants for agonist binding, channel gating and desensitization together determine steady-state dose-response profiles, the time course of individual synaptic currents and even the change in response amplitude within a synaptic train. The equilibrium constants in turn are determined by the relative free energies of the reaction ground states and, because the transition state energies are linked to those of the ground states, so too are the rate constants. In AChRs the path between DNA sequence and survival of the organism seems clear. Sequence determines the side chain, which determines  $G_B^{ACh}$  and  $G_0$ , which determine the gating rate and equilibrium constants, which determine the character of the physiological response. The mechanism of the actual work of the gating isomerization is less-well understood and may less-dependent on side chain composition. Here, it could be the overall fold of the protein that is the basis for energy transfer between the transmitter binding sites and gate. In this view, members of the AChR superfamily, which are functional as chimeras, could gate by the same essential mechanism even though they have a very low sequence homology.

## Acknowledgements

I thank Olaf Andersen and Prasad Purohit for insights and comments. Supported by NIH (NS-23513 and NS-64969).

## References

1. Sine SM. End-plate acetylcholine receptor: structure, mechanism, pharmacology, and disease. *Physiol Rev.* 2012; 92:1189–1234. [PubMed: 22811427]
2. Changeux J-P. The nicotinic acetylcholine receptor: the founding father of the pentameric ligand-gated ion channel superfamily. *Journal of Biological Chemistry.* 2012
3. Corringer P-J, Poitevin F, Prevost, Marie S, Sauguet L, Delarue M, Changeux J-P. Structure and Pharmacology of Pentameric Receptor Channels: From Bacteria to Brain. *Structure.* 2012; 20:941–956. [PubMed: 22681900]
4. Monod J, Wyman J, Changeux JP. On the Nature of Allosteric Transitions: A Plausible Model. *J Mol Biol.* 1965; 12:88–118. [PubMed: 14343300]
5. Karlin A. On the application of "a plausible model" of allosteric proteins to the receptor for acetylcholine. *J Theor Biol.* 1967; 16:306–320. [PubMed: 6048545]

6. Jackson MB. Kinetics of unliganded acetylcholine receptor channel gating. *Biophys J.* 1986; 49:663–672. [PubMed: 2421793]
7. Jackson MB. Perfection of a synaptic receptor: kinetics and energetics of the acetylcholine receptor. *Proceedings of the National Academy of Sciences.* 1989; 86:2199–2203.
8. Auerbach A. The gating isomerization of neuromuscular acetylcholine receptors. *The Journal of Physiology.* 2010; 588:573–586. [PubMed: 19933754]
9. Jadey S, Auerbach A. An integrated catch-and-hold mechanism activates nicotinic acetylcholine receptors. *J Gen Physiol.* 2012; 140:17–28. [PubMed: 22732309]
10. Chakrapani S, Bailey TD, Auerbach A. The role of Loop 5 in acetylcholine receptor channel gating. *J. Gen. Physiol.* 2003; 122:521–539. [PubMed: 14557402]
11. Jadey SV, Purohit P, Bruhova I, Gregg TM, Auerbach A. Design and control of acetylcholine receptor conformational change. *Proc Natl Acad Sci U S A.* 2011; 108:4328–4333. [PubMed: 21368211]
12. Purohit P, Auerbach A. Unliganded gating of acetylcholine receptor channels. *Proc Natl Acad Sci U S A.* 2009; 106:115–120. [PubMed: 19114650]
13. Nayak TK, Purohit PG, Auerbach A. The intrinsic energy of the gating isomerization of a neuromuscular acetylcholine receptor channel. *J Gen Physiol.* 2012; 139:349–358. [PubMed: 22547665]
14. Purohit P, Auerbach A. Energetics of gating at the apo-acetylcholine receptor transmitter binding site. *J Gen Physiol.* 2010; 135:321–331. [PubMed: 20351060]
15. Jha A, Auerbach A. Acetylcholine receptor channels activated by a single agonist molecule. *Biophys J.* 2010; 98:1840–1846. [PubMed: 20441747]
16. Lee WY, Free CR, Sine SM. Nicotinic receptor interloop proline anchors beta1-beta2 and Cys loops in coupling agonist binding to channel gating. *J Gen Physiol.* 2008; 132:265–278. [PubMed: 18663134]
17. Lee WY, Sine SM. Principal pathway coupling agonist binding to channel gating in nicotinic receptors. *Nature.* 2005; 438:243–247. [PubMed: 16281039]
18. Jha A, Cadugan DJ, Purohit P, Auerbach A. Acetylcholine receptor gating at extracellular transmembrane domain interface: the cys-loop and M2-M3 linker. *J Gen Physiol.* 2007; 130:547–558. [PubMed: 18040057]
19. Purohit P, Auerbach A. Acetylcholine receptor gating at extracellular transmembrane domain interface: the "pre-M1" linker. *J Gen Physiol.* 2007; 130:559–568. [PubMed: 18040058]
20. Cadugan DJ, Auerbach A. Linking the acetylcholine receptor-channel agonist-binding sites with the gate. *Biophys J.* 2010; 99:798–807. [PubMed: 20682257]
21. Bocquet N, Nury H, Baaden M, Le Poupon C, Changeux J-P, Delarue M, Corringer P-J. X-ray structure of a pentameric ligand-gated ion channel in an apparently open conformation. *Nature.* 2009; 457:111–114. [PubMed: 18987633]
22. Hilf RJC, Dutzler R. X-ray structure of a prokaryotic pentameric ligand-gated ion channel. *Nature.* 2008; 452:375–379. [PubMed: 18322461]
23. Hilf RJC, Dutzler R. Structure of a potentially open state of a proton-activated pentameric ligand-gated ion channel. *Nature.* 2009; 457:115–118. [PubMed: 18987630]
24. Sine SM, Ohno K, Bouzat C, Auerbach A, Milone M, Pruitt JN, Engel AG. Mutation of the acetylcholine receptor alpha subunit causes a slow-channel myasthenic syndrome by enhancing agonist binding affinity. *Neuron.* 1995; 15:229–239. [PubMed: 7619526]
25. Steinlein OK, Mulley JC, Propping P, Wallace RH, Phillips HA, Sutherland GR, Scheffer IE, Berkovic SF. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. *Nat Genet.* 1995; 11:201–203. [PubMed: 7550350]
26. Zhou M, Engel AG, Auerbach A. Serum choline activates mutant acetylcholine receptors that cause slow channel congenital myasthenic syndromes. *PNAS.* 1999; 96:10466–10471. [PubMed: 10468632]
27. Zhou M, Engel AG, Auerbach A. Serum choline activates mutant acetylcholine receptors that cause slow channel congenital myasthenic syndromes. *Proc Natl Acad Sci U S A.* 1999; 96:10466–104671. [PubMed: 10468632]


28. Cadugan DJ, Auerbach A. Linking the Acetylcholine Receptor-Channel Agonist-Binding Sites with the Gate. *Biophysical Journal*. 2010; 99:798–807. [PubMed: 20682257]
29. Dellisanti CD, Yao Y, Stroud JC, Wang Z-Z, Chen L. Crystal structure of the extracellular domain of nAChR [alpha]1 bound to [alpha]-bungarotoxin at 1.94 Å resolution. *Nat Neurosci*. 2007; 10:953–962. [PubMed: 17643119]
30. Purohit P, Auerbach A. Acetylcholine Receptor Gating: Movement in the  $\alpha$ -Subunit Extracellular Domain. *J. Gen. Physiol*. 2007; 130:569–579. [PubMed: 18040059]
31. Chakrapani S, Bailey TD, Auerbach A. Gating dynamics of the acetylcholine receptor extracellular domain. *J Gen Physiol*. 2004; 123:341–356. [PubMed: 15051806]
32. Bouzat C, Bartos M, Corradi J, Sine SM. The interface between extracellular and transmembrane domains of homomeric Cys-loop receptors governs open-channel lifetime and rate of desensitization. *J Neurosci*. 2008; 28:7808–7819. [PubMed: 18667613]
33. Bouzat C, Gumilar F, Spitzmaul G, Wang HL, Rayes D, Hansen SB, Taylor P, Sine SM. Coupling of agonist binding to channel gating in an ACh-binding protein linked to an ion channel. *Nature*. 2004; 430:896–900. [PubMed: 15318223]
34. Jha A, Gupta S, Zucker SN, Auerbach A. The energetic consequences of loop 9 gating motions in acetylcholine receptor-channels. *The Journal of Physiology*. 2012; 590:119–129. [PubMed: 22025664]
35. Xiu X, Hanek AP, Wang J, Lester HA, Dougherty DA. A Unified View of the Role of Electrostatic Interactions in Modulating the Gating of Cys Loop Receptors. *Journal of Biological Chemistry*. 2005; 280:41655–41666. [PubMed: 16216879]
36. Grutter T, de Carvalho LP, Dufresne V, Taly A, Edelstein SJ, Changeux J-P. Molecular tuning of fast gating in pentameric ligand-gated ion channels. *Proceedings of the National Academy of Sciences of the United States of America*. 2005; 102:18207–18212. [PubMed: 16319224]
37. Mercado J, Czajkowski C. Charged residues in the  $\alpha$ 1 and  $\beta$ 2 pre-M1 regions involved in GABAA receptor activation. *J Neurosci*. 2006; 26:2031–2040. [PubMed: 16481436]
38. Bafna PA, Purohit PG, Auerbach A. Gating at the Mouth of the Acetylcholine Receptor Channel: Energetic Consequences of Mutations in the  $\alpha$  M2-Cap. *Plos One*. 2008;3.
39. Cymes GD, Grosman C, Auerbach A. Structure of the transition state of gating in the acetylcholine receptor channel pore: a  $\phi$ -value analysis. *Biochemistry*. 2002; 41:5548–5555. [PubMed: 11969415]
40. Jha A, Purohit P, Auerbach A. Energy and structure of the M2 helix in acetylcholine receptor-channel gating. *Biophys J*. 2009; 96:4075–4084. [PubMed: 19450479]
41. Mitra A, Cymes GD, Auerbach A. Dynamics of the acetylcholine receptor pore at the gating transition state. *Proc. Natl Acad. Sci. USA*. 2005; 102:15069–15074. [PubMed: 16217024]
42. Purohit P, Mitra A, Auerbach A. A stepwise mechanism for acetylcholine receptor channel gating. *Nature*. 2007; 446:930–933. [PubMed: 17443187]
43. Zhu F, Hummer G. Drying transition in the hydrophobic gate of the GLIC channel blocks ion conduction. *Biophys J*. 2012; 103:219–227. [PubMed: 22853899]
44. Cadugan DJ, Auerbach A. Conformational dynamics of the  $\alpha$ M3 transmembrane helix during acetylcholine receptor channel gating. *Biophys J*. 2007; 93:859–865. [PubMed: 17513382]
45. Mitra A, Bailey TD, Auerbach AL. Structural dynamics of the M4 transmembrane segment during acetylcholine receptor gating. *Structure*. 2004; 12:1909. [PubMed: 15458639]
46. Corradi J, Spitzmaul G, De Rosa MJ, Costabel M, Bouzat C. Role of pairwise interactions between M1 and M2 domains of the nicotinic receptor in channel gating. *Biophys J*. 2007; 92:76–86. [PubMed: 17028140]
47. Bruhova I, Auerbach A. Subunit symmetry at the extracellular domain-transmembrane domain interface in acetylcholine receptor channel gating. *J Biol Chem*. 2010; 285:38898–38904. [PubMed: 20864527]
48. Purohit P, Auerbach A. Acetylcholine receptor gating: movement in the  $\alpha$ -subunit extracellular domain. *J Gen Physiol*. 2007; 130:569–579. [PubMed: 18040059]
49. Purohit P, Bruhova I, Auerbach A. Sources of energy for gating by neurotransmitters in acetylcholine receptor channels. *Proc Natl Acad Sci U S A*. 2012; 109:9384–9389. [PubMed: 22647603]



50. Zhong W, Gallivan JP, Zhang Y, Li L, Lester HA, Dougherty DA. From ab initio quantum mechanics to molecular neurobiology: a cation- $\pi$  binding site in the nicotinic receptor. *Proc Natl Acad Sci U S A*. 1998; 95:12088–12093. [PubMed: 9770444]
51. Xiu X, Puskar NL, Shanata JA, Lester HA, Dougherty DA. Nicotine binding to brain receptors requires a strong cation- $\pi$  interaction. *Nature*. 2009; 458:534–537. [PubMed: 19252481]
52. Mukhtasimova N, Free C, Sine SM. Initial Coupling of Binding to Gating Mediated by Conserved Residues in the Muscle Nicotinic Receptor. *The Journal of General Physiology*. 2005; 126:23–39. [PubMed: 15955875]
53. Corringer PJ, Bertrand S, Bohler S, Edelstein SJ, Changeux JP, Bertrand D. Critical elements determining diversity in agonist binding and desensitization of neuronal nicotinic acetylcholine receptors. *J Neurosci*. 1998; 18:648–657. [PubMed: 9425007]
54. Grutter T, Prado de Carvalho L, Le Novère N, Corringer PJ, Edelstein S, Changeux JP. An H-bond between two residues from different loops of the acetylcholine binding site contributes to the activation mechanism of nicotinic receptors. *EMBO J*. 2003; 22:1990–2003. [PubMed: 12727867]
55. Purohit P, Auerbach A. Glycine Hinges with Opposing Actions at the Acetylcholine Receptor-Channel Transmitter Binding Site. *Molecular Pharmacology*. 2011; 79:351–359. [PubMed: 21115636]
56. Gupta S, Auerbach A. Temperature dependence of acetylcholine receptor channels activated by different agonists. *Biophys J*. 2011; 100:895–903. [PubMed: 21320433]
57. Gupta S, Auerbach A. Mapping heat exchange in an allosteric protein. *Biophys J*. 2011; 100:904–911. [PubMed: 21320434]
58. Chakrapani S, Auerbach A. A speed limit for conformational change of an allosteric membrane protein. *Proc Natl Acad Sci U S A*. 2005; 102:87–92. [PubMed: 15618401]
59. Mitra A, Tascione R, Auerbach A, Licht S. Plasticity of acetylcholine receptor gating motions via rate-energy relationships. *Biophys J*. 2005; 89:3071–3078. [PubMed: 16113115]
60. Auerbach A. A statistical analysis of acetylcholine receptor activation in *Xenopus* myocytes: stepwise versus concerted models of gating. *J Physiol*. 1993; 461:339–378. [PubMed: 8350269]
61. Mukhtasimova N, Lee WY, Wang HL, Sine SM. Detection and trapping of intermediate states priming nicotinic receptor channel opening. *Nature*. 2009; 459:451–454. [PubMed: 19339970]
62. Auerbach A. Kinetic behavior of cloned mouse acetylcholine receptors. A semi-autonomous, stepwise model of gating. *Biophys J*. 1992; 62:72–73. [PubMed: 1600103]
63. Sigworth FJ. Open channel noise. I. Noise in acetylcholine receptor currents suggests conformational fluctuations. *Biophys J*. 1985; 47:709–720. [PubMed: 2410044]
64. Lape R, Colquhoun D, Sivilotti LG. On the nature of partial agonism in the nicotinic receptor superfamily. *Nature*. 2008; 454:722–727. [PubMed: 18633353]
65. Grosman C, Zhou M, Auerbach A. Mapping the conformational wave of acetylcholine receptor channel gating. *Nature*. 2000; 403:773. [PubMed: 10693806]
66. Fersht, AR. Chemical Catalysis. In *Structure and mechanism in protein science: a guide to enzyme catalysis and protein folding*. New York: W. H. Freeman and Company; 1999.
67. Grunwald E. Structure-energy relations, reaction mechanism, and disparity of progress of concerted reaction events. *Journal of the American Chemical Society*. 1985; 107:125–133.
68. Zhou Y, Pearson JE, Auerbach A.  $\Phi$ -Value analysis of a linear, sequential reaction mechanism: Theory and application to ion channel gating. *Biophys. J*. 2005; 89:3680–3685. [PubMed: 16183877]
69. Auerbach A. Gating of acetylcholine receptor channels: Brownian motion across a broad transition state. *Proceedings of the National Academy of Sciences of the United States of America*. 2005; 102:1408–1412. [PubMed: 15665102]
70. Prevost MS, Sauguet L, Nury H, Van Renterghem C, Huon C, Poitevin F, Baaden M, Delarue M, Corringer PJ. A locally closed conformation of a bacterial pentameric proton-gated ion channel. *Nat Struct Mol Biol*. 2012; 19:642–649. [PubMed: 22580559]
71. Auerbach A. Gating of acetylcholine receptor channels: brownian motion across a broad transition state. *Proc Natl Acad Sci U S A*. 2005; 102:1408–1412. [PubMed: 15665102]


72. Lape R, Plested AJ, Moroni M, Colquhoun D, Sivilotti LG. The alpha1K276E startle disease mutation reveals multiple intermediate states in the gating of glycine receptors. *J Neurosci*. 2012; 32:1336–1352. [PubMed: 22279218]
73. Lummis SC, Beene DL, Lee LW, Lester HA, Broadhurst RW, Dougherty DA. Cis-trans isomerization at a proline opens the pore of a neurotransmitter-gated ion channel. *Nature*. 2005; 438:248–252. [PubMed: 16281040]
74. Purohit P, Auerbach A. Unliganded gating of acetylcholine receptor channels. *Proceedings of the National Academy of Sciences*. 2009; 106:115–120.
75. Paulsen IM, Martin IL, Dunn SM. Isomerization of the proline in the M2-M3 linker is not required for activation of the human 5-HT3A receptor. *J Neurochem*. 2009; 110:870–878. [PubMed: 19457066]
76. Purohit P, Bruhova I, Auerbach A. Sources of energy for gating by neurotransmitters in acetylcholine receptor channels. *Proceedings of the National Academy of Sciences*. 2012; 109:9384–9389.
77. Taly A, Delarue M, Grutter T, Nilges M, Le Novere N, Corringer PJ, Changeux JP. Normal mode analysis suggests a quaternary twist model for the nicotinic receptor gating mechanism. *Biophys J*. 2005; 88:3954–3965. [PubMed: 15805177]
78. Zheng W, Auerbach A. Decrypting the sequence of structural events during the gating transition of pentameric ligand-gated ion channels based on an interpolated elastic network model. *PLoS Comput Biol*. 2011; 7:e1001046. [PubMed: 21253563]
79. Papke D, Gonzalez-Gutierrez G, Grosman C. Desensitization of neurotransmitter-gated ion channels during high-frequency stimulation: a comparative study of Cys-loop, AMPA and purinergic receptors. *J Physiol*. 2011; 589:1571–1585. [PubMed: 21300749]
80. Popescu G, Robert A, Howe JR, Auerbach A. Reaction mechanism determines NMDA receptor response to repetitive stimulation. *Nature*. 2004; 430:790–793. [PubMed: 15306812]
81. Duret G, Van Renterghem C, Weng Y, Prevost M, Moraga-Cid G, Huon C, Sonner JM, Corringer P-J. Functional prokaryotic-eukaryotic chimera from the pentameric ligand-gated ion channel family. *Proceedings of the National Academy of Sciences*. 2011; 108:12143–12148.
82. Grutter T, Prado de Carvalho L, Virginie D, Taly A, Fischer M, Changeux JP. A chimera encoding the fusion of an acetylcholine-binding protein to an ion channel is stabilized in a state close to the desensitized form of ligand-gated ion channels. *C R Biol*. 2005; 328:223–234. [PubMed: 15810546]
83. Unwin N. Refined structure of the nicotinic acetylcholine receptor at 4Å resolution. *J Mol Biol*. 2005; 346:967–989. [PubMed: 15701510]
84. Nayak TK, Purohit PG, Auerbach A. The intrinsic energy of the gating isomerization of a neuromuscular acetylcholine receptor channel. *The Journal of General Physiology*. 2012; 139:349–358. [PubMed: 22547665]
85. Celie PH, van Rossum-Fikkert SE, van Dijk WJ, Brejc K, Smit AB, Sixma TK. Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures. *Neuron*. 2004; 41:907–914. [PubMed: 15046723]
86. Gupta S, Auerbach A. Temperature Dependence of Acetylcholine Receptor Channels Activated by Different Agonists. *Biophysical Journal*. 2011; 100:895–903. [PubMed: 21320433]
87. Jadey S, Purohit P, Auerbach A. Action of nicotine and analogs on acetylcholine receptors having mutations of transmitter-binding site residue aG153. *Journal of General Physiology*.
88. Bruhova I, Gregg T, Auerbach A. Energy for wild-type acetylcholine receptor-channel gating from different choline derivatives. *Biophysical Journal*.

1. Allostery in the AChR can be studied in single molecules with electrophysiology
2. The intrinsic energy changes of the 'gating' without ligands are known
3. Most mutations change the intrinsic energy, not that from the ligand
4. The effects of most mutations are additive
5. The ligand energy is from interactions with just three amino acids




**Figure 1. AChR structure and function**

a. The *Torpedo marmorata* AChR (subunit stoichiometry  $\alpha_2\beta\delta\gamma$ ; pdb accession number 2bg9<sup>83</sup>). In adult mouse AChRs an  $\epsilon$  subunit replaces  $\gamma$ . The upper and lower arrows mark the levels of a transmitter binding site (at the subunit interface) and the gate region of the pore. b. Thermodynamic cycle for AChR activation. Horizontal arrows, binding to two equivalent binding sites (A, the agonist); vertical arrows, the gating conformational change (C and O, the closed- and open-channel ensembles of the system).  $G_O$  and  $G_C$ , the O vs. C energy difference without and with two agonist molecules bound;  $G_{LA}$  and  $G_{HA}$ , the free energy of binding, low and high affinity. From detailed balance,  $2 G_B = G_2 - G_0$ , where  $G_B = G_{HA} - G_{LA}$ .  $G_B$  is the energy from the affinity change for one agonist that serves to increase the open-channel probability.




**Figure 2. Measuring  $G_2$**

a. Outside-out patch current following a step to high [ACh] (opening downward). The rising phase is binding plus gating and the falling phase is desensitization. b. Single-channel currents in a cell-attached patch exposed continuously to 1 mM ACh. Each cluster is the binding and gating activity of a single AChR. The silent periods between clusters of openings are periods when all AChRs in the patch are desensitized. Below, higher resolution views of clusters at different [ACh]. The shut times reflect binding and opening, and the open times reflect closing. c. Sequential scheme for estimating rate and equilibrium constants with activation by agonists.  $G_2 = -0.59 \ln(f_2/b_2)$ , where  $f_2$  and  $b_2$  are the diliganded opening and closing rate constants.




### Figure 3. Measuring $G_0$

a. Continuous traces of currents obtained in the absence of agonists. Mutations that make  $G_2$  more negative to known extents (in parentheses) increase constitutive activity. Bottom, with a sufficient decrease in  $G_2$  the unliganded currents are clustered, indicating that desensitization occurs in the absence of agonists. b. The observed  $G_0$  of clusters is correlated linearly with the change in  $G_2$  caused by the background mutations (units are kcal/mol). Open and filled circles are different sets of mutation combinations. The intrinsic  $G_0$  of wt AChRs (at  $-100$  mV) is estimated by extrapolating to the condition where  $G_2 = 0$  (+8.4 kcal/mol).



**Figure 4.  $G_0$  and phi in the  $\alpha$  subunit**


a. Distributions. Top, range-energy is the difference between the smallest and largest  $G_0$  for a series of mutations of one amino acid. ~15% of residues are iso-energetic between C and O (white). Bottom, phi is the slope of a log-log plot of the forward rate vs. gating equilibrium constant and gives the relative timing of energy change, early (purple) to late (red). There are ~4 phi populations. b. Maps (view is from the  $\gamma$  subunit interface). \*, binding site; arrow marks the narrow region of the pore, alongside the M2 helix. Large range-energy residues are mainly along the subunit interface between the binding site and the gate, with some having  $\geq 4$  kcal/mol range (blue). There is approximately a decreasing, coarse-grained, longitudinal gradient in phi values.  $\alpha A96$  has the largest range-energy of any residue measured so far and a phi value that is lower than its neighbors. There is an isolated, large-range and high-phi patch of residues near the C-terminus of the M2 helix (the  $\alpha M2\text{-cap}$ ).



**Figure 5. Sources of  $G_B$**

The ligand binding site of AChBP with carbamylcholine (CCh)(pdb accession number 1uv6; <sup>85</sup>). The view is from extracellular solution of a subunit interface. Left, the ‘principal’ subunit that corresponds to  $\alpha$  in AChRs (loops A, B and C) and right, the ‘complimentary’ subunit that corresponds to  $\epsilon/\gamma$  or  $\delta$  in AChRs (loop D). An ‘aromatic triad’ (green) provides most of the  $G_B^{ACh}$  energy ( $\sim 2$  kcal/mol each, from the indole and benzene rings of TrpB, TyrC1 and TyrC2). The pink spheres are the  $C\alpha$  atoms of the residues that correspond to GlyB1, GlyB2 and ProD2 in AChRs. Mouse numbering: TyrA= $\alpha$ Y93; GlyB1= $\alpha$ G147; TrpB= $\alpha$ W149; GlyB2= $\alpha$ G153; TyrC1= $\alpha$ Y190; TyrC2= $\alpha$ Y198; TrpD= $\epsilon$ W55 or  $\delta$ W57; ProD2= $\epsilon$ P121 or  $\delta$ P123.





**Figure 6. Temperature dependence of AChR gating**

a. The slope of the van'T Hoff plot ( $\Delta G_2$  vs.  $1/T$ ) is agonist-dependent<sup>86</sup>. b. The enthalpy change (black bars) associated with most mutations is larger than the free energy change (white bars) because of a compensating entropy change. c. An example where enthalpy changes of mutations are approximately additive.

**Table 1**Net binding energy ( $G_B$ ) from different agonists

Agonist	$G_B$ (kcal/mol)
Acetylcholine <sup>11</sup>	-5.1
Anabasine <sup>87</sup>	-5.1
Nornicotine <sup>87</sup>	-4.7
Carbamylcholine <sup>11</sup>	-4.7
TMA <sup>11</sup>	-4.5
BTMA <sup>88</sup>	-4.5
DMThM <sup>11</sup>	-4.2
Nicotine <sup>87</sup>	-4.1
4OH-BTMA <sup>88</sup>	-4.1
DMT <sup>11</sup>	-4.0
DMP <sup>11</sup>	-3.9
ETMA <sup>88</sup>	-3.8
PTMA <sup>88</sup>	-3.8
Chlorocholine <sup>88</sup>	-3.7
3OH-PTMA <sup>88</sup>	-3.6
Choline <sup>11</sup>	-3.3
Cholamine (pH 9.0) <sup>88</sup>	-3.2
2OH-PTMA <sup>88</sup>	-3.0
Cholamine (pH 6.1) <sup>88</sup>	-2.1
Betaine <sup>88</sup>	-0.8

Energies calculated assuming equal contributions from two binding sites. TMA, tetramethylammonium; BTMA, butyltrimethylammonium; DMthM, 4,4-dimethylthiomorpholinium; 4OH-BTMA, 4-hydroxybutyltrimethylammonium; DMT, 1,1-dimethylthiazolidinium; DMP, 1,1-dimethylpyrrolidinium; ETMA, ethyltrimethylammonium; PTMA, propyltrimethylammonium; 3OH-PTMA, 3-hydroxypropyltrimethylammonium; 2OH-PTMA, 2-hydroxypropyltrimethylammonium